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Oxidatively modified low-density lipoprotein (ox-LDL) leads to endothelial activation,
dysfunction and injury. Recently, a novel lectin-like receptor for ox-LDL (LOX-1) has been
identified, primarily in the endothelial cells, and it allows uptake of ox-LDL into endothelial
cells. This receptor is transcriptionally upregulated by tumor necrosis factor-alpha, angioten-
sin II, shear stress and ox-LDL itself. The expression of this receptor activates a variety of
intracellular processes that lead to expression of adhesion molecules and endothelial
activation. This receptor is highly expressed in the blood vessels of animals and humans with
hypertension, diabetes mellitus and atherosclerosis. Expression of this receptor may also be
relevant in intra-arterial thrombogenesis and myocardial ischemia-reperfusion injury. Iden-
tification and regulation of this receptor and understanding of signal transduction pathways
may lead to new therapies of diseases characterized by endothelial dysfunction. (J Am Coll
Cardiol 2002;39:1429–35) © 2002 by the American College of Cardiology Foundation
Oxidative modification of low-density lipoprotein (LDL) is
a key step in the pathogenesis of atherosclerosis. Oxidized
LDL (ox-LDL), through a variety of scavenger receptors
(SR), such as SR-AI/II, CD36, SR-BI, macrosialin/CD68
and SREC, is taken up by monocytes and macrophages and
smooth muscle cells and exerts its pro-atherogenic effects on
the vessel wall (1,2). The classic SRs are absent or present in
very small amounts in endothelial cells (3). However, it has
long been suggested that endothelial cells internalize and
degrade the modified form of LDL, including ox-LDL, by
cell-surface receptors (4–6).
Oxidized LDL leads to endothelial activation, dysfunc-
tion and injury. Endothelial activation is believed to be a
very early step in the evolution of atherosclerosis. Activation
of endothelial cells results in expression of a variety of genes,
such as endothelin, tissue factor, cyclo-oxygenase, nitric
oxide synthase (NOS), growth factors and monocyte che-
moattractant protein-1 (MCP-1). It also leads to expression
of adhesion molecules to which inflammatory cells attach,
followed by a cascade of events, including cell rolling,
separation of the intercellular junction and subendothelial
migration of inflammatory cells (7–12). Oxidized LDL also
induces apoptosis in endothelial cells (13).
How endothelial cells endocytose ox-LDL is a subject of
intense investigation. In 1997, Sawamura et al. (14) iden-
tified a lectin-like receptor for ox-LDL (LOX-1) in bovine
aortic endothelial cells. Since then, a number of groups have
confirmed the presence of this specialized receptor and have
defined its regulation. A definition and understanding of the
regulation of this receptor allows the opportunity to inter-
vene at endothelial phase in disease states in which ox-LDL
plays a central role.
Lectin-like ox-LDL receptor is a type II membrane
protein (50 kDa) with a C-type lectin-like extracellular
domain and a short cytoplasmic tail. Lectin-like ox-LDL
receptor is present in the endothelium of human coronary
arteries, rabbit and rat aortae and bovine endothelial cells
(14–18). A small amount of LOX-1 has also been identified
in macrophages, platelets and smooth muscle cells (19–21).
In human coronary artery endothelial cells (HCAECs),
there is a single class of LOX-1 receptors with a Bmax of
30 ng/mg protein and KD of 1.7  10
8 mol/l, as
determined by radioligand-binding studies (16,17). An
excess of unlabeled ox-LDL inhibits iodine-125 labeled
ox-LDL binding to LOX-1, and native LDL has no effect.
Activation of LOX-1 can be blocked in a nonspecific
manner by polyinosinic acid and carrageenan, but not by the
SR blocker fucoidin (16). Recently, a specific antisense
phosphorothioate oligodeoxynucleotide directed at the 5-
coding sequence of human LOX-1 messenger ribonucleic
acid (mRNA) has been designed (22,23). This antisense
blocks the expression of LOX-1 in response to ox-LDL.
Antibodies to the ox-LDL receptor have also been devel-
oped (15).
Activators of LOX-1. LOX-1 AND ITS LIGANDS. Endothe-
lial activation or dysfunction elicited by ox-LDL and its
lipid constituents has been shown to play a crucial role in the
pathogenesis of atherosclerosis. Lectin-like ox-LDL recep-
tor was identified as the major receptor for ox-LDL in
endothelial cells. This receptor can support binding, inter-
nalization and proteolytic degradation of ox-LDL, but not
significant amounts of acetylated LDL, which is a well-
known, high-affinity ligand for class A SRs expressed by
endothelial cells (SR-EC) (14,16).
A recent study by Chen et al. (24) showed that the
lectin-like domain of LOX-1 is essential for ligand binding,
but the neck domain is not. In particular, the large loop
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between the third and fourth cysteine of the lectin-like
domain plays a crucial role for ox-LDL binding, as well as
C-terminal end-residues. Alanine-directed mutagenesis of
the basic amino acid residues around this region revealed
that all of the basic residues are involved in ox-LDL
binding. Simultaneous mutations of these basic residues
almost abolished the ox-LDL-binding activity of LOX-1.
An electrostatic interaction between basic residues in the
lectin-like domain of LOX-1 and negatively charged ox-
LDL is critical for the binding activity of LOX-1.
Moriwaki et al. (25) reported that LOX-1 binds and
degrades ox-LDL, but not acetylated LDL. Fucoidin and
maleylated bovine serum albumin, which inhibit ox-LDL
binding to class A SRs, do not inhibit ox-LDL binding or
degradation in LOX-1–expressing cells (LOX-1-CHO).
Polyinosinic acid and carrageenan, in contrast, significantly
reduce ox-LDL binding to LOX-1-CHO. Oxidized LDL
and delipidated and untreated LDL bind and are degraded
similarly in LOX-1-CHO. Taken together, these observa-
tions show that LOX-1 is a receptor for ox-LDL, but not
for acetylated LDL. LOX-1 recognizes protein moiety of
ox-LDL, and its ligand specificity is distinct from that of
other receptors for ox-LDL, including class A and B
scavenger receptors (25). It is not known whether oxidized
phospholipids and minimally oxidized LDL bind to
LOX-1.
OXIDIZED LDL AND LYSOPHOSPHOTIDYLCHOLINE. Mehta
and Li (16) and later on Aoyama et al. (26) described
upregulation of LOX-1 mRNA in cultured endothelial cells
by ox-LDL in a time-dependent fashion, with peak at 12 to
24 h of incubation in vitro. This effect of ox-LDL was
concentration-dependent (10 to 40 g/ml), with a decline
at higher concentrations, probably a reflection of cell death
at higher concentrations (80 to 100 g/ml) (13). In contrast
to ox-LDL, incubation of cells with native-LDL had no
effect on the expression of LOX-1. The induction of
LOX-1 protein is associated with an increase in mRNA,
suggesting transcriptional upregulation of LOX-1 by ox-
LDL. The upregulation of LOX-1 in response to ox-LDL
can be blocked by a specific antisense to LOX-1 mRNA
(22,23).
Lysophosphotidylcholine, which has been implicated in
atherogenesis, also induces mRNA and protein expression
of LOX-1 (26). Because lysophosphotidylcholine does not
change the half-life of LOX-1 mRNA, the upregulation of
LOX-1 appears to occur at transcriptional levels.
TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA). The cyto-
kine TNF-alpha is a pro-inflammatory cytokine. Its expres-
sion is increased in atherosclerosis, and excess production of
TNF-alpha influences plaque vulnerability (27–29). Kume
et al. (30) showed that TNF-alpha increases LOX-1 cell-
surface expression in a concentration-dependent manner,
with a peak time to expression of 8 to 12 h. Tumor necrosis
factor-alpha appeared to activate the transcription of
LOX-1, as measured by nuclear run-off assay. Another
cytokine, interferon-gamma, however, does not increase the
expression of LOX-1. It is noteworthy that TNF-alpha can
induce the expression of class A SRs in cultured vascular
smooth muscle cells (31,32), but it suppresses the expression
of class A SRs in macrophages (33).
FLUID SHEAR STRESS. Shear stress modulates the expression
of various genes in endothelial cells and is an important
determinant of endothelial cell function. Shear stress in the
physiologic range (1 to 15 dynes/cm2) was shown by Murase
et al. (34) to upregulate LOX-1 mRNA and protein in a
time-dependent fashion, with a peak at 4 and 8 h, respec-
tively. Chelation of intracellular Ca reduced shear stress-
induced LOX-1 mRNA expression, and the Ca iono-
phore ionomycine enhanced LOX-1 mRNA expression.
Upregulation of LOX-1 expression in response to fluid
shear stress may be important in endothelial cell injury and
activation.
ANGIOTENSIN II. Activation of the renin-angiotensin sys-
tem (RAS), resulting in the formation of angiotensin II, is
a critical factor in atherogenesis. Inhibition of RAS by the
angiotensin-converting enzyme has been shown to be effec-
tive in limiting atherosclerosis (35) and decreasing cardiac
events associated with atherosclerosis (36). Most of the
effects of angiotensin II are thought to be mediated by
activation of the angiotensin II type 1 (AT1) receptor.
Angiotensin II, like ox-LDL, causes endothelial apoptosis,
decreases NOS expression, stimulates reactive oxygen spe-
cies (ROS) formation and induces expression of adhesion
molecules in endothelial cells (37–40).
Angiotensin II markedly increases LOX-1 mRNA and
protein expression (17). The increase in LOX-1 expression
occurs in a concentration-dependent manner. Angiotensin
II causes an increase in ox-LDL uptake by endothelial cells,
again in a concentration-dependent manner. Angiotensin II
causes endothelial cell injury and potentiates ox-LDL–
mediated cell injury. Most importantly, these effects of
angiotensin II can be blocked by specific AT1 receptor
blockers, but not by AT2 receptor blockers. Other studies
suggest that ox-LDL upregulates angiotensin II AT1 recep-
tor expression (41). Several studies show that hypercholes-
Abbreviations and Acronyms
AT1  angiotensin II type 1
(e)NOS  (endothelial) nitric oxide synthase
HCAEC  human coronary artery endothelial cells
LDL  low-density lipoprotein
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MAPK  mitogen-activated protein kinase
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terolemia is associated with enhanced AT1 receptor expres-
sion (42,43).
These observations collectively imply the presence of the
phenomenon of cross-talk between ox-LDL and RAS in
atherosclerosis. Each of these mediators recruits the other,
and together, the two systems cause extensive cell activation,
dysfunction and injury.
LOX-1 and endothelial cell injury. A number of studies
have shown that ox-LDL causes endothelial activation,
dysfunction and injury (7,13,44). An important form of
injury that has recently attracted attention is programmed
cell death, or apoptosis. Recently, we demonstrated that
ox-LDL causes apoptosis in HCAECs in association with
upregulation of apoptotic protein Fas and downregulation
of the anti-apoptotic protein Bcl2 (13). Endothelial cell
apoptosis was characterized by fluorescent TUNEL staining
and deoxyribonucleic acid laddering. Oxidized LDL-
mediated apoptosis was associated with upregulation of
LOX-1 expression. Importantly, two different chemical
inhibitors of LOX-1, as well as a specific antisense to
LOX-1 mRNA, decreased apoptosis (22). These inhibitors
of LOX-1 activation decreased the release of lactic dehy-
drogenase, a marker of cell injury.
It is important to note that apoptosis is a common
occurrence in atherosclerosis (44) and in a number of other
atherosclerosis-related disease processes, such as myocardial
ischemia (45).
A recent study (46) from our group demonstrated that
ox-LDL decreases the expression of endothelial constitutive
NOS (eNOS) and increases the expression of the following
adhesion molecules in HCAECs: E- and P-selectins, intra-
cellular adhesion molecule-1 and vascular cell adhesion
molecule-1. Importantly, we found that LOX-1 plays a
crucial role in this setting, because inhibition of LOX-1 by
LOX-1 antisense reduces the effect of ox-LDL on the
expression of eNOS and adhesion molecules. These obser-
vations, taken together, indicate that LOX-1 plays a major
role in endothelial dysfunction and injury, leading to the
initiation and progression of atherosclerosis.
Oxidized LDL has also been well known to play a key
role in the adherence of monocytes to the activated endo-
thelium, an early step in atherogenesis (7). The intracellular
processes involved include activation of protein kinase C
and mitogen-activated protein kinase (MAPK) (47), as well
as the subsequent upregulation of MCP-1 (47–49). In
studies of HCAECs (23), we found that incubation of
endothelial cells with ox-LDL increased the phosphoryla-
tion of MAPK. In these experiments, ox-LDL also upregu-
lated MCP-1 expression (protein and mRNA) and mono-
cyte adhesion to the endothelial cells through activation of
LOX-1. The definitive evidence for the hypothesis that
LOX-1 induces upregulation of MCP-1, with subsequent
adhesion of monocytes to endothelial cells, through LOX-1
activation with activation of MAPK as a key signal trans-
duction mechanism, came from experiments in which the
antisense to LOX-1 mRNA completely blocked these
processes in endothelial cells treated with ox-LDL.
LOX-1 AND SIGNALING PATHWAYS. The signaling pathways
for ox-LDL–mediated endothelial injury include the intra-
cellularly generated ROS and activation of protein kinases
and transcription factors (50–54). Cominacini et al. (49)
showed that it is the binding of ox-LDL to LOX-1 that
initiates nuclear factor-B activation, as well as the increase
in intracellular ROS formation. These effects of ox-LDL
were blocked by a monoclonal antibody to LOX-1. Direct
evidence for ox-LDL–mediated intracellular ROS forma-
tion in endothelial cells through activation of LOX-1 has
recently been presented (50).
As mentioned earlier, treatment of HCAECs with ox-
LDL resulted in the activation of MAPK and transcrip-
tional nuclear factor-B, and subsequently expression of
several genes (22). Further experiments showed that the
antisense to LOX-1 mRNA inhibited these signal trans-
duction pathways elicited by ox-LDL (22).
A recent study (55) showed that LOX-1 expression is
associated with inactivation of the protein kinase B path-
way. Protein kinase B, the cellular homologue of v-Akt, is a
key signaling component downstream of phosphatidyl-
inositide-3 kinase (56). Activation of protein kinase B appears
to be vitally important in the expression of eNOS.
Upregulation of LOX-1, the signal conduction pathways
in its biologic effects and the role of LOX-1 in steps leading
to cell injury and ultimately atherosclerosis are summarized
in Figure 1.
Role of LOX-1 in disease states. Oxidized LDL has been
shown to activate endothelial cells as well as platelets.
Oxidized LDL decreases eNOS synthesis in endothelial
cells, platelets and leukocytes (57–59). By immunostaining,
ox-LDL has been identified in atherosclerotic plaque, par-
ticularly rupture-prone plaque (60). In addition, plasma
levels of ox-LDL are elevated in patients with acute man-
ifestations of atherosclerosis (60). Oxidized LDL has been
shown to upregulate the expression of another local medi-
ator of atherogenesis—that is, the AT1 receptor (41).
Oxidized LDL also enhances the cell-injurious effects of
angiotensin II, and angiotensin II, in turn, enhances the
expression of LOX-1 and, thereby, the cell-injurious effects
of ox-LDL (17). The crucial role of RAS activation has
been well established in patients with hypertension and
atherosclerosis. These disease states are associated with
upregulation of LOX-1, which suggests a pathogenic role of
this novel receptor, either alone or in combination with
RAS activation.
HYPERTENSION. In studies by Nagase et al. (61), sponta-
neously hypertensive rats, Wistar-Kyoto rats and Dahl
salt-sensitive and salt-resistant rats were fed a salt-loaded or
control diet. Lectin-like ox-LDL receptor mRNA, as de-
termined by Northern blot analysis, was found to be
minimal in the aorta and veins of Wistar-Koyoto rats, but
was markedly upregulated in spontaneously hypertensive
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rats. Expression of LOX-1 was lower in the aorta of Dahl
salt-resistant rats on both diets, but was higher in salt-
loaded Dahl salt-sensitive rats. These investigators also
suggested that LOX-1 expression in hypertensive rats might
be dynamically regulated. This concept is further supported
by the observations that angiotensin II upregulates LOX-1
gene expression in endothelial cells (17), and angiotensin-
converting enzyme inhibitors markedly decrease LOX-1
gene expression (62). These findings suggest that LOX-1
expression is upregulated in hypertension and may contrib-
ute to its pathogenesis. It may be speculated that enhanced
LOX-1 expression is the cause of increased ox-LDL uptake
in endothelial cells, as well as diminished endothelium-
dependent vasorelaxation in hypertension (63).
ATHEROSCLEROSIS. Chen et al. (15) showed LOX-1 ex-
pression (protein and mRNA) to be upregulated in the
aortae of eight-week-old Watanabe-heritable hyperlipid-
emic rabbits. Immunostaining showed that the augmented
expression was primarily localized within the intima at the
early stages of atherosclerosis. The most prominent staining
effect was observed in the endothelial cells of atherosclerotic
lesions; however, the endothelium of the areas without
lesions in the rabbits’ aortae also demonstrated LOX-1
accumulation, suggesting that LOX-1 may be involved in
the initiation of atherosclerosis.
We studied New Zealand White rabbits on a 10-week,
high-cholesterol diet and observed upregulation of LOX-1
gene expression in the aortae of hypercholesterolemic rab-
bits, but not in the aortae of rabbits on a regular diet (64).
Immunostaining showed that LOX-1 was present primarily
in the neointima. Importantly, treatment of rabbits with the
AT1 receptor blocker, losartan, not only decreased the
extent of atherosclerosis, but also reduced LOX-1 expres-
sion (by reverse-transcription polymerase chain reaction and
immunostaining). The vascular tissues in this model of
atherosclerosis have previously been shown to over-express
AT1 receptors (43). These observations collectively provide
in vivo evidence for cross-talk between LOX-1 accumula-
tion and AT1 receptor upregulation.
Kataoka et al. (65) examined human carotid artery end-
arterectomy specimens and showed positivity for LOX-1
expression in early atherosclerotic lesions, and the positivity
was greater in recent compared with advanced lesions. They
found that besides endothelial cells, macrophages and
smooth muscle cells in the intima of advanced atheroscle-
rotic plaques demonstrated LOX-1 positivity. In our labo-
ratory, we have identified LOX-1 expression in the intima
of the microvasculature of advanced human atherosclerotic
lesions. Furthermore, we observed co-localization of
LOX-1 in apoptotic cells on double immunostaining. The
cells expressing apoptosis and LOX-1 were endothelial cells,
smooth muscle cells and macrophages. Notably, Oka et al.
(66) have shown that LOX-1 mediates phagocytosis of aged
and apoptotic cells. These observations in atherosclerotic
tissues collectively confirm the results of in vitro studies
(13), and suggest that LOX-1 expression in the early stages
of atherosclerosis may serve to facilitate the uptake of
ox-LDL and activate endothelial cells to which inflamma-
tory cells adhere. As the process of atherogenesis progresses,
LOX-1 is expressed in the smooth muscle cells and mono-
Figure 1. Oxidized low-density lipoprotein (ox-LDL), tumor necrosis factor-alpha (TNF-), shear stress, reactive oxygen species (ROS), endothelin and
angiotensin II (Ang II) increase the expression of lectin-like oxidized low-density lipoprotein receptor (LOX-1), which activates mitogen-activated protein
kinases (MAPKs) and protein kinases (PKs), leading to activation of the transcription factor nuclear factor-B (NF-B). These steps play a crucial role in
subsequent cell injury, through release of ROS and a reduction in endothelial nitric oxide synthase (eNOS). Enhanced activity of monocyte
chemoattractant protein-1 (MCP-1) leads to expression of adhesion molecules. Simultaneously, LOX-1 activation leads to endothelial dysfunction,
apoptosis and injury. These steps are collectively involved in atherogenesis. Along with decreases in eNOS, changes in Fas and bad lead to apoptosis.
AT1  angiotensin II type 1.
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cytes and macrophages, where, in conjunction with expres-
sion of classic scavenger receptors, LOX-1 may serve to
induce apoptosis and phagocytosis.
THROMBOSIS. Thrombosis is usually the early event that
leads to acute manifestations of atherosclerosis, and platelets
are the usual initiator cells in this process (67). Platelets have
been shown to internalize ox-LDL, which serves to decrease
type 3 NOS (eNOS) activity in platelets and enhance
platelet aggregation (58). Recently, platelets have also been
shown to express a modest amount of LOX-1 (19). Kaka-
tani et al. (68), in preliminary studies, have shown that
LOX-1 antibody decreases arterial thrombus formation in
the rat. This observation provides a link between internal-
ization of ox-LDL and platelet activation and thrombosis.
MYOCARDIAL ISCHEMIA. Thrombosis formed in the coro-
nary arteries is often the most proximal cause of acute
coronary syndromes (67). Oxidized LDL is present in the
atherosclerotic tissues of rupture-prone segments (60). Fur-
thermore, the degree of myocardial ischemia is character-
ized by the oxidative state, which facilitates oxidation of
native LDL (60). An in vitro study showed that perfusion of
ox-LDL significantly decreases myocardial contraction in
the isolated heart of the rat in the Langendorff model (69).
We recently examined LOX-1 expression in the myocar-
dium of rats undergoing total coronary occlusion for 1 h,
followed by reperfusion for 2 h. In these rat hearts, we
observed extensive LOX-1 expression in the ischemic-
reperfused myocardium, but not in the hearts of rats
subjected to a sham operation. Ischemia alone did not cause
a marked upregulation of LOX-1 expression. To examine
the contributory role of LOX-1 in the determination of
infarct size and cardiac function, a group of rats was treated
with LOX-1 antibody before initiation of ischemia. We
observed a marked decrease in the expression of LOX-1 in
the myocardium of rats given the antibody. Further, there
was 48% reduction in infarct size, as well as preservation of
left ventricular function after ischemia-reperfusion in rats
given the LOX-1 antibody.
These studies imply LOX-1’s important role during
myocardial ischemia, in terms of determination of cardiac
function and infarct size.
DIABETES MELLITUS. Diabetes is characterized by a state of
oxidative stress, endothelial dysfunction and upregulated
expression of adhesion molecules in inflammatory cells. In a
rat model of diabetes in response to streptozocin, LOX-1
expression was found to be increased in the aorta of the
diabetic rat, compared with that of the nondiabetic rat (70).
Immunohistochemistry revealed that the most distinctive
staining effect of LOX-1 was in the endothelial cells,
especially in the region of bifurcation of the aorta. Further-
more, in cultured aortic endothelial cells, diabetic rat serum
and advanced glycosylation end-products induced LOX-1
expression, whereas control rat serum, along with high
glucose levels, did not. In addition, with a competitive
inhibition assay, LOX-1 ligand activity was accumulated in
the diabetic rat serum, mainly in the very-low-density
lipoprotein/LDL fractions.
Conclusions. Identification of LOX-1 and a definition of
its biologic role in pathophysiologic states provide a new
clue to the reason for uptake of ox-LDL in endothelial cells.
Internalization of ox-LDL leads to a cascade of events that
may induce a variety of diseases characterized by endothelial
dysfunction, activation and injury. Activation of endothelial
cells by ox-LDL through LOX-1 upregulation may be a key
event in hypertension, diabetes mellitus and dyslipidemia—
the most important risk factors for atherosclerosis. Cross-
talk between different systems, such as RAS and dyslipide-
mia, may serve to enhance tissue injury.
A definition of the underlying signals leading to inflam-
matory cell deposits and activation provides an opportunity
to understand the disease process and to design novel
therapies in the management of atherosclerosis.
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